Nytt från hematologi
Obesity and the Risk of MGUS and Myeloma Progression
/ Sæmundur Rögnvaldsson
EHA 2026: Long-Term Outcomes with Zanubrutinib in First-Line CLL
/ Wojciech Jurczak
Hematologi publikationer
Hematology • Meet the Experts
EHA 2026: Germline Testing Beyond Family History in AML and MDS
/ Panagiotis Baliakas
EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma
/ Astrid Hundebøll Torpe
AML highlights
AML Insights – July-August Update: What’s New in the Field
/ Amanda Feldballe Bernholm / Jan Andreasen
Nordic AML Insights – July-August Update
/ Amanda Feldballe Bernholm / Jan Andreasen
AML Insights – June Update: What’s New in the Field
/ Jan Andreasen
AML Insights: What’s New in the Field
/ Jan Andreasen
EHA 2026: Increased Risk of Psychotropic Drug Use Observed in Patients with Mastocytosis
/ Maren Poulsgaard Jørgensen
Serious Illness Conversations and End-of-Life Care in Hematological Cancer
/ Cæcilie Borregaard Myrhøj
EHA 2026: Comparable Outcomes with Reduced-Dose Treosulfan
/ Johanne Skovgaard Schovsbo










































